Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Ivermectin for Atopic Dermatitis
NCT03553615Phase 2Withdrawn
- Sponsor
- Stanford University
- Start
- Dec 2030
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CHILD-IVITAB in atopic dermatitis (AD), sponsored by Stanford University. Primary endpoint: Dermatology Life Quality Index at 8 weeks. Planned start Dec 2030; status: withdrawn.
02
Drugs
CHILD-IVITAB
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03553615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03553615.